Funding Opportunities

We invest millions of dollars every year to support cutting-edge research across the translational pipeline from basic science to early-phase clinical trials as well as funding projects focused on other important areas, such as prevention, assistive technology, quality of care, workforce development and research infrastructure.  

Many of our awards are offered annually, but some are one-time only grants. All our programs require a letter of intent (LOI) followed by a full proposal (by invitation only). You can learn more on our Information for Applicants and Awardees page.

Requests for Applications

The Lawrence and Isabel Barnett Drug Development Program 

Description: This program supports the preclinical development of new or repurposed treatments for ALS. 
Funding: Up to $500,000 over 2 years 
LOI Deadline (CLOSED): December 18, 2023, 5 p.m. US ET
Full Proposal Deadline (by invitation only): March 7, 2024, 5 p.m. US ET  

The Hoffman Clinical Trial Awards Program 

Description: This program supports early- to mid-stage (phase 1 or 2a) interventional clinical trials of novel or repositioned therapeutics for ALS. 
Funding: Up to $1,000,000 over 2–3 years 
LOI Deadline (CLOSED): January 25, 2024, 5 p.m. US ET 
Full Proposal Deadline (by invitation only): April 12, 2024, 5 p.m. US ET

Milton Safenowitz Postdoctoral Fellowship Program

Description: This program supports the development of early career scientists by funding junior postdoctoral fellows doing research of high scientific merit and relevance to ALS. 
Funding: Up to $150,000 over 2 years 
This opportunity has closed. 

Learn About All Our Awards and Programs

Additional Funding Opportunities 

Breakthrough Research and Innovation in Drug Development Grants

Funding Organization: Critical Path Institute’s Translational Therapeutics Accelerator
Description: These awards are designed to support academic researchers in traversing the drug development valley of death by funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
Funding: There are three funding levels. Stage 1: up to $250,000 for 1 year (total cost). Stage 2: up to $500,000 for 1 year (total cost). Stage 3: up to $1,000,000 for 1 year (total cost).
Deadline: March 31, 2024

Natural History, Clinical Outcome Assessment and Biomarker Studies of Rare Neurodegenerative Diseases (U01 Clinical Trials Optional)

Funding Organization: U.S. Food and Drug Administration 
Description:  This funding opportunity is intended to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults.
Funding: Application budgets are not limited but should reflect the actual needs of the proposed project, including both direct and indirect costs for up to 4 years of support.
Deadline: May 6, 2024

Addressing Rare Diseases

Funding Organization: Patient-Centered Outcomes Research Institute (PCORI)
Description: This opportunity seeks to fund high-quality, patient-centered comparative clinical effectiveness research projects focused on rare diseases, like ALS. PCORI is particularly interested in submissions that address approaches to symptom management, timely diagnosis, and improving care delivery for individuals with rare diseases.
Funding: Direct costs up to $12 million for up to 5 years
Open Date: May 7, 2024
Applicant Town Hall: May 14, 2024, 12–1 p.m. ET (Click here to register.)
LOI Deadline: June 4, 2024, 5 p.m. ET

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) 

Funding Organization: U.S. Food and Drug Administration 
Description: This program funds clinical trials evaluating the efficacy and/or safety of existing products in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions, such as ALS. 
Funding: Up to $650,000 per year for 4 years 
Open Date: August 23, 2024 

Want to add your funding opportunity to this list? Contact us at ResearchGrants@als.org

ALS Research Updates 
Be among the first to know about new funding opportunities and get other information specifically for researchers by subscribing to receive email updates. 
Print Friendly and PDF